Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
…
continue reading
HemeTalks: Conversations in Hematology Education is the latest podcast channel by the American Society of Hematology (ASH)! Explore educational content crafted by subject-matter experts from ASH, tailored to fulfill your professional education requirements. Whether you are a clinician or researcher, HemeTalks provides innovative education designed for every career stage and subspecialty.
…
continue reading
Mayo Clinic Healh Matters brings you the latest medical advice, news and research to help you live a happier, healthier life. Join host Kristen Meinzer in conversation with Mayo Clinic’s leading medical experts as she asks all the questions you’re eager to (or maybe even afraid to) ask, letting curiosity lead the way. Wondering if you might have ADHD? Or how your pet affects your health? Be part of an informative—and fun—discussion about one of the most important topics: your health.
…
continue reading
I used to think that being a good dad was all about managing the chaos. Providing, being a good husband, feeding the dogs, volunteering at school, and making sure the homework gets done. And, if you can do all that in a nice suburban neighborhood, you're probably really doing well. I checked these boxes on most days and figured I was doing alright. Then, on Nov. 1, 2015, my daughter Galia said "Dad, my leg hurts." I thought it was nothing; it turns out it was something. Acute Myeloid Leukemi ...
…
continue reading
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
…
continue reading
America's first radio talk show dedicated to overcoming chronic pain. Hear exclusive interviews and personal stories from celebrity guests. No one is immune to pain, but together we can overcome it.
…
continue reading
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company. Podcasts are intended for licensed adul ...
…
continue reading
As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoke ...
…
continue reading
1
Advancing Sickle Cell Disease Care: Navigating Gene Therapy
17:11
17:11
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
17:11
Are you a hematologist or a generalist provider seeking clarity on how to best counsel patients with sickle cell disease (SCD) who are interested in gene therapy? Join us for a podcast session focused on important patient considerations for gene therapy, tailored for SCD providers and clinicians. This session aims to provide practical insights to f…
…
continue reading
1
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
13:53
13:53
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
13:53
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including: Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advan…
…
continue reading
1
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
13:46
13:46
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
13:46
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including: Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC Long-term safety observations for cri…
…
continue reading
1
Should I Be Signing Up for a Polar Bear Plunge?
31:13
31:13
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
31:13
Sweating. Freezing. Sweating. Freezing. That's the “nordic cycle,” or alternating between a sauna and cold water. More spas are offering both hot and cold therapies as part of their services, and at-home sauna tents and ice baths are becoming more and more popular. But how beneficial are these methods of extreme temperature exposure for your health…
…
continue reading
1
ROS1-Alterations and Molecular Testing in Advanced NSCLC
16:28
16:28
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
16:28
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA …
…
continue reading
1
Updates in Thalassemia: New Challenges and Novel Treatment Approaches
20:19
20:19
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
20:19
Speakers: Alexis Thompson, MD, and Sujit Sheth, MD Description: For general hematologists with a foundational understanding of thalassemia, this episode discusses the changing demographics due to immigration and refugee resettlement. It covers the diagnosis process from newborn screening to older individuals, emphasizing genetic testing due to nume…
…
continue reading
1
Who's Afraid of Brain-Eating Amoebas?
27:59
27:59
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
27:59
In 2023, both a toddler in Arkansas and a swimmer in Texas died from the infection of a brain-eating amoeba, Naegleria fowleri, likely contracted from local water sources. ""Brain-eating amoebas"" is a scary headline that sounds like something out of the Twilight Zone, but just how worried should we be? And how serious are the ramifications of infe…
…
continue reading
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma
1:02:03
1:02:03
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:02:03
Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma.Von Neil Love, MD
…
continue reading
Distraction runs rampant in our society — we can all relate. But when you have ADHD, navigating a chaotic world can be especially challenging. And adult ADHD is on the rise. During the pandemic, diagnoses and prescriptions for ADHD in adults increased significantly. So what’s driving this increase in diagnoses? And how do you tell if you yourself h…
…
continue reading
Join host Kristen Meinzer in conversation with Mayo Clinic’s leading medical experts as she asks all the questions you’re eager to (or maybe even afraid to) ask, letting curiosity lead the way. Wondering if you might have ADHD? Or how your pet affects your health? Be part of an informative—and fun—discussion about one of the most important topics: …
…
continue reading
We're excited to introduce our new show, Health Matters, where we're talking with leading medical experts from Mayo Clinic about their insights and opinions on the latest health and wellness subjects and information. New episodes starting August 6 right here in your feed. Find us online at Mayo Clinic Press for more health and wellness articles, po…
…
continue reading
1
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
49:32
49:32
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
49:32
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup …
…
continue reading
1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
34:45
34:45
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
34:45
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…
…
continue reading
1
Current Clinical Practice and NCCN Guidelines for CLL/SLL
31:33
31:33
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
31:33
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…
…
continue reading
1
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma
1:00:49
1:00:49
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:00:49
Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.…
…
continue reading
1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
28:35
28:35
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
28:35
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…
…
continue reading
1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
24:23
24:23
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
24:23
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…
…
continue reading
HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated ca…
…
continue reading
Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden. Furthermore, the st…
…
continue reading
1
Immune-Related Adverse Events Predict Response to Checkpoint Inhibitor Monotherapy in Advanced Head & Neck Cancers
6:28
Patients who had immune-related adverse events had better responses and lived longer than those who didn’t. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting.OncTimesTalk reporter Pete…
…
continue reading
1
A Multi-Drug Algorithm Used to Accurately Predict Best First-Line Treatments in Patients With Newly Diagnosed Acute Myeloid Leukemia
7:39
A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of L…
…
continue reading
1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
24:30
24:30
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
24:30
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…
…
continue reading
1
Congress to Clinic: Expert Takeaways on Emerging Data for AML
25:21
25:21
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
25:21
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…
…
continue reading
1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
19:19
19:19
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
19:19
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…
…
continue reading
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis
1:00:06
1:00:06
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:00:06
Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.Von Neil Love, MD
…
continue reading
When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34…
…
continue reading
1
Telehealth Triumphs for Palliative Care Delivery in Patients With Lung Cancer
14:15
14:15
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
14:15
Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it’s also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular. For the Oncology Times podcast, OncT…
…
continue reading
1
Lymphadenectomy Can Be Safely Omitted for Patients With Advanced Epithelial Ovarian Cancer Lacking Suspicious Lymph Nodes
10:53
10:53
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
10:53
The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of N…
…
continue reading
1
Neoadjuvant Checkpoint Inhibitor Combination Beats Standard Surgery With Adjuvant Immunotherapy in Macroscopic, Resectable Stage III Melanoma
11:34
11:34
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
11:34
A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut…
…
continue reading
1
Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia
9:25
Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital,…
…
continue reading
1
Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma
6:52
Treatment with perioperative chemotherapy, with chemotherapy before and after surgery, brought superior outcomes for patients with locally advanced esophageal adenocarcinoma, in research reported to the 2024 ASCO Annual Meeting. Lead author Jens Höppner FAChirg, FACS, MD, Director of the Department of Surgery in the University Medical Center at the…
…
continue reading
1
Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy
8:13
Data from the DESTINY Breast06 trial using the antibody-drug conjugate trastuzumab deruxtecan to treat patients with estrogen receptor positive (HR+), human epidermal growth factor receptor-low (HER2-low), and HER2-ultralow breast cancer after endocrine therapy, show longer progression-free survival in comparison with standard chemotherapy. After a…
…
continue reading
1
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
8:50
New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progre…
…
continue reading
1
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer
11:34
11:34
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
11:34
When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study r…
…
continue reading
1
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic
17:36
17:36
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
17:36
An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the confe…
…
continue reading
1
Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences
1:16:45
1:16:45
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:16:45
Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.Von Neil Love, MD
…
continue reading
1
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma
10:31
10:31
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
10:31
The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia …
…
continue reading
1
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC
8:21
A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR An…
…
continue reading
1
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes
13:46
13:46
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
13:46
A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, re…
…
continue reading
1
Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
33:54
33:54
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
33:54
Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Von Neil Love, MD
…
continue reading
1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma
42:08
42:08
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
42:08
Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.Von Neil Love, MD
…
continue reading
1
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic
17:35
17:35
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
17:35
An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice Pre…
…
continue reading
1
Exercise Deters Prostate Cancer Death & Progression
10:24
10:24
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
10:24
Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or met…
…
continue reading
1
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers
9:31
Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease pr…
…
continue reading
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia
1:02:06
1:02:06
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:02:06
Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.Von Neil Love, MD
…
continue reading
1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25:55
25:55
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
25:55
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
…
continue reading
1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47:23
47:23
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
…
continue reading
1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series
1:01:09
1:01:09
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:01:09
Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.Von Neil Love, MD
…
continue reading
1
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
15:07
15:07
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
15:07
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After…
…
continue reading
1
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
12:50
12:50
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
12:50
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San …
…
continue reading